{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:33:16Z","timestamp":1783103596200,"version":"3.54.6"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.01.011","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T17:51:34Z","timestamp":1674669094000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It"],"prefix":"10.1016","volume":"23","author":[{"given":"Anand A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.01.011_bib0001","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","article-title":"How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"132","author":"Odenike","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0003","first-page":"5336","article-title":"Outcome of patients with IDH1\/2-mutated post\u2013myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood advances","volume":"4","author":"Chifotides","year":"2020","journal-title":"Am Soc Hematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of Myeloid Neoplasms and Acute Leukemia: integrating Morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.011_bib0006","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2022-157603","article-title":"Outcomes of patients with accelerated\/blast-phase Myeloproliferative Neoplasms in the current era of Myeloid Therapies","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.01.011_bib0008","doi-asserted-by":"crossref","first-page":"318-27. e6","DOI":"10.1016\/j.clml.2020.12.024","article-title":"Clinical significance of bone marrow blast percentage in patients with Myelofibrosis and the effect of Ruxolitinib Therapy","volume":"21","author":"Masarova","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.01.011_bib0009","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.01.011_bib0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0011","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0012","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0014","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0016","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0017","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/hematology.2020000129","article-title":"Genomics of MPN progression","volume":"2020","author":"Patel","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.01.011_bib0018","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0020","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0021","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2737","article-title":"Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data","volume":"38","author":"Palandri","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.01.011_bib0022","first-page":"2","volume":"136","author":"Drummond","year":"2020","journal-title":"Am Soc Hematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0023","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.011_bib0024","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0025","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0026","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0027","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bmt.2014.31","article-title":"Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran\u00e7aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"49","author":"Cahu","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2023.01.011_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.01.011_bib0029","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.011_bib0030","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","article-title":"Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0031","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0032","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0033","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2023.01.011_bib0034","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2012-07-445635","article-title":"BCL-2 inhibition with ABT-737 prolongs survival in an NRAS\/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells","volume":"122","author":"Beurlet","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0035","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clml.2023.01.011_bib0036","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2023.01.011_bib0037","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0038","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute Myeloid Leukaemia: a post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of Navitoclax to ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.011_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106456","article-title":"Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm","volume":"98","author":"Tremblay","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.01.011_bib0041","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.011_bib0042","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.01.011_bib0043","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.26381","article-title":"Multicenter evaluation of efficacy and toxicity of venetoclax based combinations in patients with accelerated and blast phase myeloproliferative neoplasms","volume":"97","author":"King","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.01.011_bib0044","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0045","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0046","article-title":"JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2023.01.011_bib0047","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","article-title":"Oncogenic activities of IDH1\/2 Mutations: from Epigenetics to Cellular Signaling","volume":"27","author":"M Gagn\u00e9","year":"2017","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.clml.2023.01.011_bib0048","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2023.01.011_bib0049","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.011_bib0050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0051","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0052","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0053","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.011_bib0054","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.01.011_bib0055","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2022-164678","article-title":"Molecularly targeted combination therapy for advanced phase Myeloproliferative Neoplasm: MPN-RC 119","volume":"140","author":"Bar-Natan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.011_bib0056","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 Is a Tumor suppressor in the progression of Myeloproliferative Neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.01.011_bib0057","doi-asserted-by":"crossref","unstructured":"Kong T, Laranjeira ABA, Yang K, , et\u00a0al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat Cancer 2022; doi: 10.1038\/s43018-022-00486-8","DOI":"10.1038\/s43018-022-00486-8"},{"key":"10.1016\/j.clml.2023.01.011_bib0058","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.01.011_bib0059","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-021-00487-3","article-title":"Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells","volume":"11","author":"Fiskus","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.01.011_bib0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-022-00618-4","article-title":"Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary AML cells","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:52Z","timestamp":1761871372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000290"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}